<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118274</url>
  </required_header>
  <id_info>
    <org_study_id>11491</org_study_id>
    <secondary_id>UVACC-34104</secondary_id>
    <secondary_id>UVACC-MEL-44</secondary_id>
    <secondary_id>UVACC-GCRC-CLS013</secondary_id>
    <secondary_id>UVACC-HITC-02620</secondary_id>
    <secondary_id>MDA-2005-0070</secondary_id>
    <nct_id>NCT00118274</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma</brief_title>
  <official_title>A Multicenter Trial to Evaluate the Effects of Administration of Cyclophosphamide and Melanoma-Derived Helper Peptides on the Immunogenicity of a Class I MHC-Restricted Peptide-Based Vaccine in Participants With Resected Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Craig L Slingluff, Jr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from peptides may help the body build an effective immune response&#xD;
      to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Cyclophosphamide may also stimulate the immune system in different ways and stop&#xD;
      tumor cells from growing. Giving vaccine therapy together with cyclophosphamide after surgery&#xD;
      may cause a stronger immune response to kill any remaining tumor cells. It may also prevent&#xD;
      or delay the recurrence of melanoma.&#xD;
&#xD;
      PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy&#xD;
      when given with or without cyclophosphamide and to see how well they work in treating&#xD;
      patients who have undergone surgery for stage II, stage III, or stage IV melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of adjuvant vaccine therapy comprising multi-epitope melanoma&#xD;
           peptides (MP) and multi-epitope melanoma helper peptides (MHP) emulsified in Montanide&#xD;
           ISA-51 in patients with resected stage IIB-IV melanoma.&#xD;
&#xD;
        -  Determine the safety of administering cyclophosphamide before vaccination in these&#xD;
           patients.&#xD;
&#xD;
        -  Compare the magnitude of immune response against vaccination comprising MP in&#xD;
           combination with either MHP or tetanus toxoid helper peptide (TET) emulsified in&#xD;
           Montanide ISA-51 with vs without cyclophosphamide in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the response rate and persistence of immune responses in patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Compare the magnitude of immune response against vaccination comprising TET or MHP with&#xD;
           vs without cyclophosphamide in these patients.&#xD;
&#xD;
        -  Compare the response rate and persistence of immune response against vaccination&#xD;
           comprising TET or MHP with vs without cyclophosphamide in these patients.&#xD;
&#xD;
        -  Determine the delayed-type hypersensitivity response to the peptide components of these&#xD;
           vaccines in these patients.&#xD;
&#xD;
        -  Compare, preliminarily, disease-free survival of patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified&#xD;
      according to HLA-type (HLA-A1 positive vs HLA-A2 positive, HLA-A1 negative, or -A3 negative&#xD;
      vs HLA-A3 positive, or -A1 negative) and participating center (University of Virginia [UVA]&#xD;
      vs non-UVA). Patients are randomized to 1 of 4 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive vaccine comprising multi-epitope melanoma peptides (MP) and&#xD;
           tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally (ID) and&#xD;
           subcutaneously (SC) on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
&#xD;
        -  Arm II: Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then&#xD;
           receive vaccine as in arm I.&#xD;
&#xD;
        -  Arm III: Patients receive vaccine comprising MP and multi-epitope melanoma helper&#xD;
           peptides emulsified in Montanide ISA-51 ID and SC on days 1, 8, 15, 29, 36, 43, 85, 183,&#xD;
           274, and 365.&#xD;
&#xD;
        -  Arm IV: Patients receive cyclophosphamide as in arm II. Patients then receive vaccine as&#xD;
           in arm III.&#xD;
&#xD;
      Treatment in all arms continues in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for 2 years and&#xD;
      then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 173 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2005</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the Peptide Vaccines</measure>
    <time_frame>30 days after receiving the last dose of study drug, up to week 52</time_frame>
    <description>Number of participants with dose-limiting toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity (CD8+ T Cell Response to 12 Melanoma Peptides, 12MP) as Measured by Elispot Assay, up to Day 50</measure>
    <time_frame>50 days</time_frame>
    <description>The primary end point was the maximum cumulative circulating CD8+ T cell response to 12 melanoma peptides (12MP) measured by ELISpot assay over the first six vaccines (to day 50).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">170</enrollment>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
    <description>Given intradermally and subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>melanoma helper peptide vaccine</intervention_name>
    <description>Given intradermally and subcutaneously</description>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>multi-epitope melanoma peptide vaccine</intervention_name>
    <description>Given intradermally and subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm III</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tetanus toxoid helper peptide</intervention_name>
    <description>Given intradermally and subcutaneously</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_label>Arm IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed melanoma&#xD;
&#xD;
               -  Cutaneous, mucosal, or primary melanoma&#xD;
&#xD;
               -  Stage IIB-IV disease&#xD;
&#xD;
          -  Has undergone surgical resection or stereotactic radiosurgery for malignant melanoma ≥&#xD;
             1 week but ≤ 6 months ago&#xD;
&#xD;
               -  No clinical or radiological evidence of disease after surgical resection or&#xD;
                  stereotactic radiosurgery by chest x-ray or CT scan*, abdominal and pelvic CT&#xD;
                  scan*, and head CT scan or MRI NOTE: *Positron emission tomography scan/CT fusion&#xD;
                  scan may replace scans of the chest, abdomen, and pelvis&#xD;
&#xD;
          -  Must have ≥ 2 intact (undissected) axillary and/or inguinal lymph node basins&#xD;
&#xD;
          -  HLA-A1, -A2, or -A3 positive AND HLA-DR1, -DR4, -DR11, -DR13, or -DR15 positive&#xD;
&#xD;
          -  Ineligible for OR refused interferon&#xD;
&#xD;
          -  No ocular melanoma&#xD;
&#xD;
          -  Brain metastases allowed provided all of the following criteria are met:&#xD;
&#xD;
               -  No more than 3 total brain metastases&#xD;
&#xD;
               -  Each metastasis ≤ 2 cm in diameter at the time of study entry&#xD;
&#xD;
               -  Each metastasis was completely removed by surgery or treated with stereotactic&#xD;
                  radiosurgery&#xD;
&#xD;
               -  No evidence of brain metastasis progression since the most recent treatment&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 2.5 times ULN&#xD;
&#xD;
          -  Lactic dehydrogenase ≤ 1.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
          -  Hepatitis C negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No known or suspected allergy to any component of the study vaccines&#xD;
&#xD;
          -  No autoimmune disorder with visceral involvement&#xD;
&#xD;
          -  No prior or active autoimmune disorder requiring cytotoxic or immunosuppressive&#xD;
             therapy&#xD;
&#xD;
          -  The following immunologic conditions are allowed:&#xD;
&#xD;
               -  Laboratory evidence of autoimmune disease (e.g., positive anti-nuclear antibody&#xD;
                  titer) without symptoms&#xD;
&#xD;
               -  Clinical evidence of vitiligo&#xD;
&#xD;
               -  Other forms of depigmenting illness&#xD;
&#xD;
               -  Mild arthritis requiring non-steroidal anti-inflammatory drugs&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Weight ≥ 110 lbs&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
               -  Hemoglobin A1C &lt; 7%&#xD;
&#xD;
          -  No medical contraindication or potential problem that would preclude study compliance&#xD;
&#xD;
          -  No other malignancy except squamous cell or basal cell skin cancer without known&#xD;
             metastasis, carcinoma in situ of the breast (ductal or lobular) or cervix, or other&#xD;
             successfully treated cancer without distant metastasis with no evidence of recurrence&#xD;
             or metastasis for &gt; 5 years&#xD;
&#xD;
          -  No known active addiction to alcohol or drugs&#xD;
&#xD;
          -  No recent (within the past year) or ongoing illicit IV drug use&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No prior vaccination with any of the synthetic peptides used in this study&#xD;
&#xD;
               -  Prior vaccinations (containing agents other than the synthetic peptides used in&#xD;
                  this study) that resulted in recurrent disease during or after vaccine&#xD;
                  administration allowed provided the last vaccination was administered more than&#xD;
                  12 weeks ago&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent interferon (e.g., Intron-A®),&#xD;
             interleukins (e.g., Proleukin®), or growth factors (e.g., Procrit®, Aranesp®, or&#xD;
             Neulasta®)&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent allergy desensitization injections&#xD;
&#xD;
          -  No influenza vaccines for at least 2 weeks before or after study vaccine&#xD;
             administration&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No concurrent chemotherapy, including nitrosoureas&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior and no concurrent oral or parenteral corticosteroids&#xD;
&#xD;
          -  No prior or concurrent inhaled steroids (e.g., Advair®, Flovent®, or Azmacort®)&#xD;
&#xD;
          -  Prior or concurrent topical corticosteroids allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since other prior and no concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior and no other concurrent investigational agents&#xD;
&#xD;
          -  More than 30 days since prior and no concurrent participation in another clinical&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Craig L. Slingluff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M. D. Anderson Cancer Center at University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, von Mehren M, Grosh WW. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol. 2011 Jul 20;29(21):2924-32. doi: 10.1200/JCO.2010.33.8053. Epub 2011 Jun 20.</citation>
    <PMID>21690475</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <results_first_submitted>January 2, 2021</results_first_submitted>
  <results_first_submitted_qc>March 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 20, 2021</results_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Craig L Slingluff, Jr</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>stage II melanoma</keyword>
  <keyword>stage III melanoma</keyword>
  <keyword>stage IV melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>Arm II</title>
          <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
        </group>
        <group group_id="P3">
          <title>Arm III</title>
          <description>Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously</description>
        </group>
        <group group_id="P4">
          <title>Arm IV</title>
          <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>Arm II</title>
          <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
        </group>
        <group group_id="B3">
          <title>Arm III</title>
          <description>Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously</description>
        </group>
        <group group_id="B4">
          <title>Arm IV</title>
          <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="44"/>
            <count group_id="B5" value="170"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety of the Peptide Vaccines</title>
        <description>Number of participants with dose-limiting toxicities</description>
        <time_frame>30 days after receiving the last dose of study drug, up to week 52</time_frame>
        <population>Intent to treat population including 167 eligible and 3 ineligible.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Arm IV</title>
            <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of the Peptide Vaccines</title>
          <description>Number of participants with dose-limiting toxicities</description>
          <population>Intent to treat population including 167 eligible and 3 ineligible.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="43"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity (CD8+ T Cell Response to 12 Melanoma Peptides, 12MP) as Measured by Elispot Assay, up to Day 50</title>
        <description>The primary end point was the maximum cumulative circulating CD8+ T cell response to 12 melanoma peptides (12MP) measured by ELISpot assay over the first six vaccines (to day 50).</description>
        <time_frame>50 days</time_frame>
        <population>All eligible participants, total = 167.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Arm II</title>
            <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
          </group>
          <group group_id="O3">
            <title>Arm III</title>
            <description>Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously</description>
          </group>
          <group group_id="O4">
            <title>Arm IV</title>
            <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity (CD8+ T Cell Response to 12 Melanoma Peptides, 12MP) as Measured by Elispot Assay, up to Day 50</title>
          <description>The primary end point was the maximum cumulative circulating CD8+ T cell response to 12 melanoma peptides (12MP) measured by ELISpot assay over the first six vaccines (to day 50).</description>
          <population>All eligible participants, total = 167.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously</description>
        </group>
        <group group_id="E2">
          <title>Arm II</title>
          <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising multi-epitope melanoma peptides, tetanus toxoid helper peptide emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
tetanus toxoid helper peptide: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
        </group>
        <group group_id="E3">
          <title>Arm III</title>
          <description>Patients receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously</description>
        </group>
        <group group_id="E4">
          <title>Arm IV</title>
          <description>Patients receive cyclophosphamide IV over 30-60 minutes on day -4. Patients then receive vaccine comprising melanoma peptides and multi-epitope melanoma helper peptides emulsified in Montanide ISA-51 intradermally and subcutaneously on days 1, 8, 15, 29, 36, 43, 85, 183, 274, and 365.&#xD;
incomplete Freund's adjuvant: Given intradermally and subcutaneously&#xD;
melanoma helper peptide vaccine: Given intradermally and subcutaneously&#xD;
multi-epitope melanoma peptide vaccine: Given intradermally and subcutaneously&#xD;
cyclophosphamide: Given IV</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <description>decreased hemoglobin</description>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Edema: limb</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Mucositis (clinical exam) - Oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pain - headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - extremity - limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pain - joint</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pain - muscle</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pain - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration - agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Mood alteration - anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - throat/pharynx/larynx</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Nasal/paranasal reaction</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>hypopigmentation</sub_title>
                <description>vitiligo</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Ulceration</sub_title>
                <description>ulceration at vaccine site</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Craig Slingluff</name_or_title>
      <organization>University of Virginia</organization>
      <phone>4349249311</phone>
      <email>cls8h@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

